Literature DB >> 31822869

Acidity changes immunology: a new VISTA pathway.

Kathleen M Mahoney1,2, Gordon J Freeman3.   

Abstract

Year:  2020        PMID： 31822869     DOI： 10.1038/s41590-019-0563-2

Source DB:  PubMed          Journal:  Nat Immunol        ISSN： 1529-2908            Impact factor:   25.606


× No keyword cloud information.
  5 in total

Review 1.  IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy.

Authors:  Xi-Yang Tang; Yan-Lu Xiong; Xian-Gui Shi; Ya-Bo Zhao; An-Ping Shi; Kai-Fu Zheng; Yu-Jian Liu; Tao Jiang; Nan Ma; Jin-Bo Zhao
Journal:  Biomark Res       Date:  2022-07-13

Review 2.  VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.

Authors:  Long Yuan; Jahnavi Tatineni; Kathleen M Mahoney; Gordon J Freeman
Journal:  Trends Immunol       Date:  2021-01-23       Impact factor: 16.687

3.  Targeting the pH Paradigm at the Bedside: A Practical Approach.

Authors:  Tomas Koltai
Journal:  Int J Mol Sci       Date:  2020-12-03       Impact factor: 5.923

4.  Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner.

Authors:  Dipti Thakkar; Shalini Paliwal; Bhushan Dharmadhikari; Siyu Guan; Lillian Liu; Shreya Kar; Nikhil K Tulsian; Joshua J Gruber; Leah DiMascio; Konrad H Paszkiewicz; Piers J Ingram; Jerome D Boyd-Kirkup
Journal:  J Immunother Cancer       Date:  2022-02       Impact factor: 13.751

5.  Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and an immune-suppressive microenvironment.

Authors:  Yan Tang; David J Kwiatkowski; Elizabeth P Henske
Journal:  Nat Commun       Date:  2022-08-26       Impact factor: 17.694
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.